Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $208.14M rose 59.8% year over year, ahead of the +55.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 12.5% from the prior quarter. Over 3 fiscal years it compounded at +53.0% a year.

Context

  • Selling, general & admin amounted to 89.4% of revenue in FY2025, down 17.3 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 16 analysts of $1.4B (+145.4%) for the fiscal year ending Dec 2026, a step up from the +38.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$208.14M+12.5% QoQ
Last fiscal yearDec 2025
$570.6M+38.7% YoY
LTMJun 2026
$712.67M+55.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.8%+143.4%+83.6 pp
1 year+38.7%+145.4%+106.7 pp
3-year CAGR+53.0%+74.2%+21.2 pp
5-year CAGR+55.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
570.6M USD
Year-over-year change
+38.7%
4-year CAGR
+71.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 selling, general & admin of $712.67M is the 3rd highest of the 11 companies compared; the peer median is $105.92M.
  • Its year-over-year change of +55.0% is the 4th highest of 11, against a peer median of +24.8%.
  • Selling, general & admin amounts to 91.8% of revenue for AXSM, versus a peer median of 67.5%.
AXSM Competitors Peer median
Selling, General & Admin for AXSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$1.56B -12.2%+8.5%33.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.43B +24.9%+15.4%38.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$712.67M +55.0%+53.0%91.8%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$560.88M +68.6%+8.8%67.5%
DNLIDenali Therapeutics Inc.LTM Jun 2026$139.03M +19.2%+2.4%3857.6%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$117.61M +115.1%-0.3%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$94.24M +24.7%+34.4%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$84.34M +86.2%+17.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$34.27M +37.9%+181.0%171.4%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$12.8M +10.2%+1.9%—
Peer median (excluding AXSM) $105.92M+24.8%+12.1%67.5%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050.04M270.6M385.69M638.5M
Cost of Revenue05.2M26.07M33.3M47.48M
Gross Profit044.84M244.54M352.39M591.02M
Gross Margin—89.6%90.4%91.4%92.6%
Research & Development58.06M57.95M97.94M187.08M183.28M
Selling, General & Admin66.65M159.25M323.12M411.36M570.6M
Operating Expenses124.71M224.64M476.36M632.95M760.25M
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
EBITDA(124.63M)(175.4M)(224.99M)(272.6M)(168.08M)
EBITDA Margin—-350.5%-83.1%-70.7%-26.3%
Operating Income(124.71M)(179.8M)(231.83M)(280.56M)(169.24M)
Operating Margin—-359.3%-85.7%-72.7%-26.5%
Interest Income00009.37M
Interest Expense5.7M7.34M6.45M6.57M6.56M
Other Income / Expenses(5.7M)(7.34M)(6.45M)(6.57M)(14.47M)
Income Before Tax(130.4M)(187.13M)(238.28M)(287.13M)(183.7M)
Pre-Tax Margin—-374.0%-88.1%-74.4%-28.8%
Income Tax Expense00960K85K(530K)
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Net Margin—-374.0%-88.4%-74.5%-28.7%
EPS (Basic)(3.47)(4.60)(5.27)(5.99)(3.68)
EPS (Diluted)(3.47)(4.60)(5.27)(5.99)(3.68)
Weighted Avg Shares37.62M40.66M45.43M47.91M49.75M
Weighted Avg Shares (Diluted)37.62M40.66M45.43M47.91M49.75M

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.